Vertex Gets Euro Panel Nod for Cystic Fibrosis Combo for Kids

 - If approved, more than 1,500 children would be eligible for a medicine that can treat the underlying cause of their disease for the first time -

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

https://finance.yahoo.com/news/vertex-receives-chmp-positive-opinion-122700787.html